• 1
    Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda , MD : National Institutes of Health; 2003. NIH Publication No. 03-5233.
  • 2
    Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:10031010.
  • 3
    Foot DK, Lewis RP, Pearson TA, et al. Demographics and cardiology, 1950–2050. J Am Coll Cardiol. 2000;35(4):10671081.
  • 4
    Heart Disease and Stroke Statistics-2003 Update. Dallas , TX : American Heart Association; 2002.
  • 5
    Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):19031913.
  • 6
    Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305313.
  • 7
    Franklin SS, Gustin W IV, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96(1):308315.
  • 8
    Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37(3):869874.
  • 9
    Messerli FH, Sundgaard-Riise K, Ventura HO, et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet. 1983;2(8357):983986.
  • 10
    Weidmann P, De Myttenaere-Bursztein S, Maxwell MH, et al. Effect on aging on plasma renin and aldosterone in normal man. Kidney Int. 1975;8(5):325333.
  • 11
    Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of SBP in older Americans. Hypertension. 2000;35:10211024.
  • 12
    Thomas F, Rudnichi A, Bacri AM, et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension. 2001;37(5):12561261.
  • 13
    Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156(16):17891796.
  • 14
    Harrington F, Saxby BK, McKeith IG, et al. Cognitive performance in hypertensive and normotensive older subjects. Hypertension. 2000;36(6):10791082.
  • 15
    Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:13471351.
  • 16
    Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol. 2001;153(1):7278.
  • 17
    Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: metaanalysis of outcome trials. Lancet. 2000;355(9207):865872.
  • 18
    Moser M, Hebart P, Hennekens CH. An overview of the meta-analysis of the hypertension treatment trials. Arch Intern Med. 1991;151:12771279.
  • 19
    Lever AF, Ramsay LE. Treatment of hypertension in the elderly. J Hypertens. 1995;13(6):571579.
  • 20
    Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35(5):10251030.
  • 21
    Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and elderly BP control in the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Hypertension. 2001;37:1218.
  • 22
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of BP control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393405.
  • 23
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 24
    Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDIANA Group. Lancet. 1999, 353:793796.